Neuroone Medical Technologies is trading at $1.85 (9.3% up) in after-hours trading as investors react to positive Mayo Clinic physician experience data for its OneRF epilepsy ablation system.
- The study highlighted meaningful seizure reductions and favorable usability feedback, reinforcing the technology’s clinical potential.
- The after-hours move follows an initial intraday surge on August 4, suggesting sustained investor interest in the company's medical advancements.
- Market enthusiasm for the OneRF system comes amid a broadly risk-on backdrop, supporting the stock's upward momentum.